{Reference Type}: Journal Article
{Title}: Engineered T Cell Receptor for Cancer Immunotherapy.
{Author}: Lee SW;Lee HM;
{Journal}: Biomol Ther (Seoul)
{Volume}: 32
{Issue}: 4
{Year}: 2024 Jul 1
{Factor}: 4.231
{DOI}: 10.4062/biomolther.2023.197
{Abstract}: Among the therapeutic strategies in cancer immunotherapy-such as immune-modulating antibodies, cancer vaccines, or adoptive T cell transfer-T cells have been an attractive target due to their cytotoxicity toward tumor cells and the tumor antigen-specific binding of their receptors. Leveraging the unique properties of T cells, chimeric antigen receptor-T cells and T cell receptor (TCR)-T cells were developed through genetic modification of their receptors, enhancing the specificity and effectiveness of T cell therapy. Adoptive cell transfer of chimeric antigen receptor-T cells has been successful for the treatment of hematological malignancies. To expand T cell therapy to solid tumors, T cells are modified to express defined TCR targeting tumor associated antigen, which is called TCR-T therapy. This review discusses anti-tumor T cell therapies, with a focus on engineered TCR-T cell therapy. We outline the characteristics of TCR-T cell therapy and its clinical application to non-hematological malignancies.